AMPK activator (aminoimidazole carboxamide ribonucleotide) researched as an exercise mimetic for endurance, fat oxidation, and metabolic regulation.
Last Updated: May 2026
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide; also called acadesine) is a small-molecule AMPK (AMP-activated protein kinase) activator researched as an exercise mimetic for endurance, fat oxidation, and metabolic regulation. Despite frequent grouping with peptides, AICAR is not a peptide — it is a nucleotide analog. It is not approved for general therapeutic use and is prohibited by WADA (World Anti-Doping Agency) as a metabolic modulator on the Prohibited List.
AICAR is a cell-permeable nucleotide analog that is converted intracellularly to ZMP (AICA ribotide), a direct activator of AMP-activated protein kinase (AMPK) — the central energy-sensing kinase that regulates fatty acid oxidation, glucose uptake, mitochondrial biogenesis, and autophagy in response to cellular energy stress. AMPK activation by AICAR mimics aspects of the cellular response to exercise without the actual physical activity, giving rise to the "exercise mimetic" framing. Evidence level: Preclinical (extensive rodent and cell culture); limited human clinical research (cardiac surgery, leukemia).
In a landmark 2008 study by Narkar et al. (Cell), AICAR administration in mice increased endurance capacity by approximately 44% without physical training and shifted muscle fiber composition toward oxidative phenotypes. Subsequent rodent studies have replicated metabolic effects on fat oxidation, glucose handling, and mitochondrial function. Limited human clinical work has been conducted in cardiac surgery (acadesine as a cardioprotective agent) and certain hematologic conditions, with mixed results. No published Phase 3 efficacy trials exist for exercise capacity, weight loss, or metabolic indications in humans. Evidence level: Preclinical (extensive); human clinical (limited and indication-specific).
AICAR's mechanism (direct AMPK activation) is distinct from GLP-1 agonism, GIP/glucagon agonism, or NNMT inhibition. It is the most-studied compound in the "exercise mimetic" category but has not produced clinical efficacy at scale comparable to GLP-1-class weight-loss compounds.
| Compound | Mechanism | Primary research focus | Evidence stage |
|---|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon | Weight loss, diabetes | Phase 3 |
| MOTS-c | Mitochondrial-derived, AMPK | Insulin sensitivity, exercise | Preclinical + Phase 1 |
| AICAR | Direct AMPK activation | Exercise mimicry, endurance, fat oxidation | Preclinical extensive; human limited |
In limited human clinical trials of acadesine for cardiac surgery, side effects have generally been mild — typically transient hypotension and hyperuricemia. Preclinical rodent studies have not surfaced significant toxicity at researched doses. Long-term safety in humans for exercise-mimetic dosing is unknown. The WADA prohibition reflects performance-enhancement concerns rather than identified safety problems. Evidence level: Limited human safety data (specific indications); preclinical rodent safety.
AICAR (acadesine) is not approved for general therapeutic use anywhere in the world as of May 2026. It is prohibited by WADA on the Prohibited List as a metabolic modulator (Section S4.5) and is banned in competitive sport. Possession is legal in most jurisdictions for research use but use by competitive athletes results in sanctions. Regulatory and anti-doping context in are peptides legal.
AICAR is a nucleotide analog with synthesis processes different from peptide synthesis — HPLC and mass spectrometry remain relevant verification tools, but with different reference standards than peptide compounds. The relatively niche demand also means fewer laboratories produce AICAR at scale, creating wider purity variance. Independent third-party testing is essential. Guidance in how-to-test-peptides hub (note: peptide-specific protocols don't all apply directly).
Peptigrity purchases AICAR vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.
No. AICAR is a nucleotide analog (specifically, an analog of adenosine monophosphate), not a peptide. It is grouped with peptides in research-chemical catalogs because of overlapping buyer audience and metabolic research interest.
Yes. AICAR is on the WADA Prohibited List (Section S4.5 — Metabolic Modulators) and competitive athletes testing positive face sanctions. Modern WADA testing methods detect AICAR and its metabolites. For broader drug-testing context, see do peptides show up on drug tests.
AICAR is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is prohibited by WADA for competitive sport. Possession by non-athletes for research use is generally legal; use by competitive athletes results in anti-doping sanctions. Country breakdown in peptide legal status guide.
Human clinical evidence for endurance improvement from AICAR is essentially absent — the "endurance mimetic" finding comes from a 2008 mouse study by Narkar et al. (Cell). Human translation has not been clinically established. Anyone seeking evidence-based endurance enhancement should not assume the mouse data applies directly.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation appropriate to a nucleotide analog. COA interpretation in red flags in peptide certificates of analysis.
No. AICAR is not approved for human consumption, is WADA-prohibited, and Peptigrity is an independent review platform, not a medical authority. Research-use dosing varies widely in community protocols. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. AICAR is not approved by the FDA or any other regulator for general therapeutic use and is prohibited by WADA in competitive sport. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.